Prevention of bone metastases and management of bone health in early breast cancer

Breast Cancer Research

Volumn 12, Issue 6, 2010, Pages

  Gnant, Michael ^a   Hadji, Peyman ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; GOSERELIN; IBANDRONIC ACID; LETROZOLE; PAMIDRONIC ACID; RISEDRONIC ACID; TAMOXIFEN; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ANTINEOPLASTIC ACTIVITY; BONE DENSITY; BONE MARROW; BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PREVENTION; CANCER STAGING; CANCER SURVIVAL; DISTANT METASTASIS; DRUG MECHANISM; HUMAN; MOLECULARLY TARGETED THERAPY; OSTEOLYSIS; OSTEOPENIA; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT PLANNING; TUMOR MICROENVIRONMENT; ADJUVANT CHEMOTHERAPY; BONE; BONE TUMOR; BREAST TUMOR; DRUG EFFECT; FEMALE; METASTASIS; PATHOLOGY; TREATMENT OUTCOME;

BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DIPHOSPHONATES; FEMALE; HUMANS; TREATMENT OUTCOME;

EID: 79960677540     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2768     Document Type: Review

References (50)

1. Hadji P, Body J-J, Aapro MS, Brufsky A, Coleman RE, Guise T, Lipton A, Tubiana-Hulin M. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 2008, 19:1407-1416. 10.1093/annonc/mdn164, 18448451.
2. Aguirre-Ghiso JA. The problem of cancer dormancy: understanding the basic mechanisms and identifying therapeutic opportunities. Cell Cycle 2006, 5:1740-1743. 10.4161/cc.5.16.3165, 2587296, 16929164.
3. Meads MB, Hazlehurst LA, Dalton WS. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 2008, 14:2519-2526. 10.1158/1078-0432.CCR-07-2223, 18451212.
4. Shiozawa Y, Havens AM, Pienta KJ, Taichman RS. The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites. Leukemia 2008, 22:941-950. 10.1038/leu.2008.48, 18305549.
5. Coleman RE. Skeletal complications of malignancy. Cancer 1997, 80(8 Suppl):1588-1594. 10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G, 9362426.
6. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002, 2:563-572. 10.1038/nrc865, 12154349.
7. Bellahcene A, Bachelier R, Detry C, Lidereau R, Clezardin P, Castronovo V. Transcriptome analysis reveals an osteoblast-like phenotype for human osteotropic breast cancer cells. Breast Cancer Res Treat 2007, 101:135-148. 10.1007/s10549-006-9279-8, 17028989.
8. Bidard FC, Vincent-Salomon A, Gomme S, Nos C, de Rycke Y, Thiery JP, Sigal-Zafrani B, Mignot L, Sastre-Garau X, Pierga JY. Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse. Clin Cancer Res 2008, 14:3306-3311. 10.1158/1078-0432.CCR-07-4749, 18519757.
9. Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, Schlimok G, Diel IJ, Gerber B, Gebauer G, Pierga JY, Marth C, Oruzio D, Wiedswang G, Solomayer EF, Kundt G, Strobl B, Fehm T, Wong GY, Bliss J, Vincent-Salomon A, Pantel K. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005, 353:793-802. 10.1056/NEJMoa050434, 16120859.
10. Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, Doyle GV, Matera J, Allard WJ, Miller MC, Fritsche HA, Hortobagyi GN, Terstappen LW. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005, 23:1420-1430. 10.1200/JCO.2005.08.140, 15735118.
11. Normanno N, Gallo M, Lamura L, De Luca A. Effect of zoledronic acid acts on the interaction between mesenchymal stem cells and breast cancer cells within the bone microenvironment [abstract 10602]. J Clin Oncol 2010, 28(15 Suppl):748s.
12. Todaro M, D'Asaro M, Caccamo N, Iovino F, Francipane MG, Meraviglia S, Orlando V, La Mendola C, Gulotta G, Salerno A, Dieli F, Stassi G. Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes. J Immunol 2009, 182:7287-7296. 10.4049/jimmunol.0804288, 19454726.
13. Coleman RE, Winter MC, Cameron D, Bell R, Dodwell D, Keane MM, Gil M, Ritchie D, Passos-Coelho JL, Wheatley D, Burkinshaw R, Marshall SJ, Thorpe H, . AZURE (BIG01/04) Investigators The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer 2010, 102:1099-1105. 10.1038/sj.bjc.6605604, 20234364, AZURE (BIG01/04) Investigators.
14. Eidtmann H, de Boer R, Bundred N, Llombart-Cussac A, Davidson N, Neven P, von Minckwitz G, Miller J, Schenk N, Coleman R. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST study. Ann Oncol 2010, 21:2188-2194. 10.1093/annonc/mdq217, 20444845.
15. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rücklinger E, Greil R, Marth C. ABCSG-12 Trial Investigators Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009, 360:679-691. 10.1056/NEJMoa0806285, 19213681, ABCSG-12 Trial Investigators.
16. Aft R, Naughton M, Trinkaus K, Watson M, Ylagan L, Chavez-MacGregor M, Zhai J, Kuo S, Shannon W, Diemer K, Herrmann V, Dietz J, Ali A, Ellis M, Weiss P, Eberlein T, Ma C, Fracasso PM, Zoberi I, Taylor M, Gillanders W, Pluard T, Mortimer J, Weilbaecher K. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol 2010, 11:421-428. 10.1016/S1470-2045(10)70054-1, 20362507.
17. Lin AY, Park JW, Scott J, Melisko M, Goga A, Moasser MM, Moore DH, Rugo HS. Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow [abstract 559]. J Clin Oncol 2008, 26(15 Suppl):20S.
18. Rack B, Schindlbeck C, Strobl B, Sommer H, Friese K, Janni W. Efficacy of zoledronate in treating persisting isolated tumor cells in bone marrow in patients with breast cancer. A phase II pilot study. Dtsch Med Wochenschr 2008, 133:285-289. 10.1055/s-2008-1046707, 18253918.
19. Rack BK, Jueckstock J, Genss E-M, Schoberth A, Schindlbeck C, Strobl B, Heinrigs M, Rammel G, Zwingers T, Sommer H, Friese K, Janni W. Effect of zoledronate on persisting isolated tumor cells in the bone marrow of patients without recurrence of early breast cancer [abstract 511]. Breast Cancer Res Treat 2007, 106(Suppl 1):S40.
20. Solomayer E, Gebauer G, Hirnle P, Janni W, Lück HJ, Becker S, Huober J, Kraemer B, Wackwitz B, Fehm T. Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients [abstract 2048]. Cancer Res 2008, 69(2 Suppl):170s-171s.
21. Greenberg S, Park JW, Melisko ME, Goga A, Moasser MM, Anderson M, Scott JH, Petrillo LA, Moore DH, Rugo HS. Effect of adjuvant zoledronic acid (ZOL) on disseminated tumor cells (DTC) in the bone marrow (BM) of women with early-stage breast cancer (ESBC): updated results [abstract 1002]. J Clin Oncol 2010, 28(15 Suppl):114s.
22. Diel IJ, Jaschke A, Solomayer EF, Gollan C, Bastert G, Sohn C, Schuetz F. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol 2008, 19:2007-2011. 10.1093/annonc/mdn429, 2733118, 18664560.
23. Powles T, Paterson A, McCloskey E, Schein P, Scheffler B, Tidy A, Ashley S, Smith I, Ottestad L, Kanis J. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res 2006, 8:R13. 10.1186/bcr1384, 1557723, 16542503.
24. Saarto T, Blomqvist C, Virkkunen P, Elomaa I. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 2001, 19:10-17.
25. Saarto T, Vehmanen L, Virkkunen P, Blomqvist C. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 2004, 43:650-656. 10.1080/02841860410032885, 15545185.
26. Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M, Bastert G. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998, 339:357-363. 10.1056/NEJM199808063390601, 9691101.
27. Ha TC, Li H. Meta-analysis of clodronate and breast cancer survival. Br J Cancer 2007, 96:1796-1801. 10.1038/sj.bjc.6603661, 2359972, 17325699.
28. Kristensen B, Ejlertsen B, Mouridsen HT, Jensen MB, Andersen J, Bjerregaard B, Cold S, Edlund P, Ewertz M, Kamby C, Lindman H, Nordenskjöld B, Bergh J. Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncol 2008, 47:740-746. 10.1080/02841860801964988, 18465343.
29. Gnant M, Mlineritsch B, Stoeger G, Luschin-Ebengreuth G, Poestlberger S, Dubsky PC, Jakesz R, Singer CF, Eidtmann H, Greil R. Mature results from ABCSG-12: adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive early breast cancer [abstract 533]. J Clin Oncol 2010, 28(15 Suppl):75s.
30. Chlebowski RT, Chen Z, Cauley JA, Anderson G, Rodabough RJ, McTiernan A, Lane DS, Manson JE, Snetselaar L, Yasmeen S. Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol 2010, 28:3582-3590. 10.1200/JCO.2010.28.2095, 20567009.
31. Rennert G, Pinchev M, Rennert HS. Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol 2010, 28:3577-3581. 10.1200/JCO.2010.28.1113, 20567021.
32. Newcomb PA, Trentham-Dietz A, Hampton JM. Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. Br J Cancer 2010, 102:799-802. 10.1038/sj.bjc.6605555, 20160722.
33. Fogelman I, Blake GM, Blamey R, Palmer M, Sauerbrei W, Schumacher M, Serin D, Stewart A, Wilpshaar W. Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Osteoporos Int 2003, 14:1001-1006. 10.1007/s00198-003-1508-y, 14530912.
34. Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 2001, 19:3306-3311.
35. Eastell R, Adams JE, Coleman RE, Howell A, Hannon RA, Cuzick J, Mackey JR, Beckmann MW, Clack G. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 2008, 26:1051-1057. 10.1200/JCO.2007.11.0726, 18309940.
36. Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN, Tozer RG, Palmer MJ, Shepherd LE, Liu S, Tu D, Goss PE. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 2006, 24:3629-3635. 10.1200/JCO.2005.05.4882, 16822845.
37. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005, 365:60-62. 10.1016/S0140-6736(05)74803-0, 15639680.
38. Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005, 353:2747-2757. 10.1056/NEJMoa052258, 16382061.
39. Lester JE, Dodwell D, Purohit OP, Gutcher SA, Ellis SP, Thorpe R, Horsman JM, Brown JE, Hannon RA, Coleman RE. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 2008, 14:6336-6342. 10.1158/1078-0432.CCR-07-5101, 18829518.
40. Confavreux CB, Fontana A, Guastalla JP, Munoz F, Brun J, Delmas PD. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. Bone 2007, 41:346-352. 10.1016/j.bone.2007.06.004, 17618847.
41. Singh S, Cuzick J, Edwards R, Blake G, Truscott J, Coleman R, Eastell R, Howell A. Effect of anastrozole on bone mineral density after one year of treatment: results from bone sub-study of the International Breast Cancer Intervention Study (IBIS-II) [abstract 28]. Breast Cancer Res Treat 2007, 106(Suppl 1):S9.
42. Van Poznak C, Hannon RA, Mackey JR, Campone M, Apffelstaedt JP, Clack G, Barlow D, Makris A, Eastell R. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol 2010, 28:967-975. 10.1200/JCO.2009.24.5902, 20065185.
43. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kässmann H, Piswanger-Sölkner JC, Seifert M, Ploner F, Menzel C, Dubsky P, Fitzal F, Bjelic-Radisic V, Steger G, Greil R, Marth C, Kubista E, Samonigg H, Wohlmuth P, Mittlböck M, Jakesz R, . Austrian Breast and Colorectal Cancer Study Group (ABCSG) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 2008, 9:840-849. 10.1016/S1470-2045(08)70204-3, 18718815, Austrian Breast and Colorectal Cancer Study Group (ABCSG).
44. Brufsky AM, Bosserman LD, Caradonna RR, Haley BB, Jones CM, Moore HCF, Jin L, Warsi GM, Ericson SG, Perez EA. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 2009, 9:77-85. 10.3816/CBC.2009.n.015, 19433387.
45. Llombart A, Frassoladti A, Paija O, Sleeboom HP, Jerusalem G, Mebis J, Deleu I, Miller J, Schenk N, Neven P. Effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E-ZO-FAST 36-month follow-up [abstract 213]. Proceedings of the American Society of Clinical Oncology 2009 Breast Cancer Symposium; 8-10 October 2009; San Francisco , http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=70&abstractID=40178
46. Hines SL, Sloan JA, Atherton PJ, Perez EA, Dakhil SR, Johnson DB, Reddy PS, Dalton RJ, Mattar BI, Loprinzi CL. Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy. Breast 2010, 19:92-96. 10.1016/j.breast.2009.12.001, 20079640.
47. Brufsky A, Harker WG, Beck JT, Carroll R, Jin L, Warsi G, Argonza-Aviles E, Ericson SG, Perez EA. The effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: the Z-FAST study 5-year final follow-up [abstract 4083]. Cancer Res 2009, 69(24 Suppl):733s-734s.
48. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, Cauley JA, Blumenstein BA, Albain KS, Lipton A, Brown S, . American Society of Clinical Oncology American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003, 21:4042-4057. 10.1200/JCO.2003.08.017, 12963702, American Society of Clinical Oncology.
49. Reid DM, Doughty J, Eastell R, Heys SD, Howell A, McCloskey EV, Powles T, Selby P, Coleman RE. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev 2008, 34(Suppl 1):S3-S18. 10.1016/j.ctrv.2008.03.007, 18515009.
50. Body JJ, Bergmann P, Boonen S, Boutsen Y, Devogelaer JP, Goemaere S, Reginster JY, Rozenberg S, Kaufman JM. Management of cancer treatment-induced bone loss in early breast and prostate cancer - a consensus paper of the Belgian Bone Club. Osteoporos Int 2007, 18:1439-1450. 10.1007/s00198-007-0439-4, 17690930.